Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology
Molecular Oncology · 2026-10 · 20 (10) · 2410-2423
DOI: 10.1002/1878-0261.70303 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 10.07.2026. Verfasst von Ik Soo Kim. Beteiligte Einrichtung: Department of Microbiology, Gachon University College of Medicine, Incheon, South Korea. Hauptthemen laut MEDLINE: DNA Methylation, Single-Cell Analysis, Neoplasms, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Samsung Science and Technology Foundation.
Abstract (Originalsprache)
Cancer is an intrinsically heterogeneous disease characterized by distinct malignant subclones defined by specific genetic and epigenetic alterations, such as aberrant DNA methylation. Traditional bulk sequencing methods analyze large populations of cells in aggregate, yielding an averaged methylome signal that masks the rare but clinically significant epigenetic patterns driving tumor initiation, metastasis, and therapeutic resistance. The emergence of single‐cell DNA methylation (scDNAme) sequencing has driven a paradigm shift in oncology by providing the resolution required to dissect this intratumoral heterogeneity. By profiling the epigenome of individual cells, scDNAme analysis enables the discovery of novel aberrant patterns, the precise reconstruction of cellular lineages, and the characterization of specific populations—such as cancer stem cells (CSCs) or drug‐resistant clones—that possess distinct methylome signatures. This technological advance is not merely an incremental improvement; it is a prerequisite for understanding core cancer hallmarks, such as the evasion of growth control and resistance to apoptosis, which are frequently governed by these specific subclones. This review specifically provides a comprehensive comparative overview evaluating the technical and chemical capabilities of emerging single‐cell modalities to distinguish DNA methylation profiles. By highlighting the strategic workflows of these emergent technologies alongside advanced computational tools, we emphasize how resolving these discrete cytosine variants empowers precise cell lineage tracing, the identification of refractory clones, and the implementation of locus‐specific epigenetic editing therapies against causal tumor subclones.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Gachon University College of Medicine, Incheon, South Korea.
ORCID-Profile: Ik Soo Kim
Förderung
- National Research Foundation of Korea
- Samsung Science and Technology Foundation
Zitieren
APA
Kim, I. S. (2026). Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology. Molecular Oncology, 20(10), 2410-2423. https://doi.org/10.1002/1878-0261.70303
Vancouver
Kim IS. Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology. Molecular Oncology. 2026;20(10):2410-2423. doi:10.1002/1878-0261.70303
BibTeX
@article{Kim2026,
author = {Kim, Ik Soo},
title = {Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {10},
pages = {2410--2423},
doi = {10.1002/1878-0261.70303}
}
EUVIMED